<?xml version="1.0" encoding="UTF-8"?>
<!-- generated by CLiX/Wiki2XML [MPI-Inf, MMCI@UdS] $LastChangedRevision: 92 $ on 16.04.2009 17:42:01[mciao0826] -->
<!DOCTYPE article SYSTEM "../article.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
<header>
<title>Gamma-Linolenic acid</title>
<id>806075</id>
<revision>
<id>236537808</id>
<timestamp>2008-09-05T22:19:41Z</timestamp>
<contributor>
<username>Rjwilmsi</username>
<id>203434</id>
</contributor>
</revision>
<categories>
<category>Lipids</category>
<category>Fatty acids</category>
</categories>
</header>
<bdy>
<p>

<table style="float: right; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" width="250px" class="toccolours" border="1">
<header colspan="2" style="width: 30%; background: #F8EABA; text-align: center;">
<b>γ-linolenic acid</b></header>
<row>
<col colspan="2" align="center" bgcolor="#ffffff">
 <image width="400px" src="GLAnumbering.png">
</image>
</col>
</row>


<row>
<col>
 <link xlink:type="simple" xlink:href="../503/3141503.xml">
IUPAC name</link></col>
<col>
all-<it>cis</it>-6,9,12-octadecatrienoic acid</col>
</row>
<row>
<col>
Other names</col>
<col>
Gamma-linolenic acid, GLA</col>
</row>
<row>
<header>
style="background: #F8EABA; text-align: center;" colspan="2"</header>
<header>
style="background: #F8EABA; text-align: center;" colspan="2"</header>
<col colspan="2" style="width: 30%; background: #F8EABA; text-align: center;">
 Except where noted otherwise, data are given for materials in their <link xlink:type="simple" xlink:href="../224/240224.xml">
standard state(at 25&nbsp;°C, 100&nbsp;kPa)</link></col>
</row>
</table>

For an explanation of <it>n</it> and numerical nomenclature (such as <it>n</it>−6 or 18:3), see <link xlink:type="simple" xlink:href="../975/10975.xml#xpointer(//*[./st=%22Nomenclature%22])">
Nomenclature of fatty acids</link>.</p>
<p>

<b><link xlink:type="simple" xlink:href="../257/12257.xml">
γ</link>-Linolenic acid</b> (<b>gamma-linolenic acid</b> or <b>GLA</b>, sometimes called <b>gamolenic acid</b>) is an <link xlink:type="simple" xlink:href="../948/105948.xml">
essential fatty acid</link> found primarily in vegetable oils.  It is sold as a dietary supplement for treating problems with <link xlink:type="simple" xlink:href="../425/70425.xml">
inflammation</link> and auto-immune diseases.  The efficacy of such use is disputed.</p>

<sec>
<st>
Chemistry</st>
<p>

GLA is categorized as an <link xlink:type="simple" xlink:href="../218/681218.xml">
<it>n</it>−6</link> (also called ω−6 or omega-6) fatty acid, meaning that the first double bond on the methyl end (designated with <it>n</it> or ω) is the sixth bond. In physiological literature, GLA is designated as 18:3 (<it>n</it>−6). Chemically, GLA is a <link xlink:type="simple" xlink:href="../099/6099.xml">
carboxylic acid</link> with an 18-carbon chain and three <it><link xlink:type="simple" xlink:href="../445/9130445.xml">
cis</link></it> <link xlink:type="simple" xlink:href="../246/6246.xml">
double bond</link>s. It is an <link xlink:type="simple" xlink:href="../339/19600339.xml">
isomer</link> of <link xlink:type="simple" xlink:href="../316/153316.xml">
α-linolenic acid</link>, which is the <link xlink:type="simple" xlink:href="../594/22594.xml">
<it>n</it>−3 fatty acid</link> found in flax seed.  </p>

</sec>
<sec>
<st>
History</st>
<p>

GLA was first isolated from the seed oil of <link xlink:type="simple" xlink:href="../991/589991.xml">
evening primrose</link>.  This herbal plant was grown by <ethnic_group wordnetid="107967382" confidence="0.8">
<group wordnetid="100031264" confidence="0.8">
<link xlink:type="simple" xlink:href="../376/2402376.xml">
Native American</link></group>
</ethnic_group>
s to treat swelling in the body.
In the 17th century, it was introduced to Europe and became a popular folk remedy, earning the name <it>king's cure-all.</it>
in 1919, Heiduschka and Lüft extracted the oil from evening primrose seeds and described an unusual linolenic acid, which they name γ-.
Later, the exact chemical structure was characterized by Riley.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%221%22])">1</ref></p>
<p>

Although there are α- and γ- forms of linolenic acid, there is no β- form.  One was once identified but it turned out to be an artifact of the original analytical process.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%222%22])">2</ref></p>

</sec>
<sec>
<st>
Dietary Sources</st>
<p>

GLA is obtained from vegetable oils, such as evening primrose (<it><plant wordnetid="103956922" confidence="0.8">
<structure wordnetid="104341686" confidence="0.8">
<artifact wordnetid="100021939" confidence="0.8">
<building_complex wordnetid="102914991" confidence="0.8">
<link xlink:type="simple" xlink:href="../661/2102661.xml">
Oenothera biennis</link></building_complex>
</artifact>
</structure>
</plant>
</it>) oil, <link xlink:type="simple" xlink:href="../161/172161.xml">
blackcurrant</link> seed oil, <link xlink:type="simple" xlink:href="../698/616698.xml">
borage</link> oil and <link xlink:type="simple" xlink:href="../313/963313.xml">
hemp</link> seed oil, and from <link xlink:type="simple" xlink:href="../626/460626.xml">
spirulina</link>, a <link xlink:type="simple" xlink:href="../618/129618.xml">
cyanobacterium</link>.  Each contains varying amounts of the fatty acid, with borage oil usually being the most heavily concentrated form.  All are widely available in <link xlink:type="simple" xlink:href="../350/297350.xml">
pharmacies</link>, <link xlink:type="simple" xlink:href="../962/2873962.xml">
health food store</link>s, or <link xlink:type="simple" xlink:href="../379/1118379.xml">
online shop</link>s.</p>
<p>

The human body produces GLA from <link xlink:type="simple" xlink:href="../497/880497.xml">
linoleic acid</link> (LA). This reaction is catalized by Δ6-<link xlink:type="simple" xlink:href="../428/4074428.xml">
desaturase</link> (D6D), an enzyme which allows the creation of a double bond on the sixth carbon counting from the carboxyl terminus.  LA is consumed sufficiently in most diets, from such abundant sources as <link xlink:type="simple" xlink:href="../873/422873.xml">
cooking oil</link>s and <link xlink:type="simple" xlink:href="../940/18940.xml">
meat</link>s. However, a lack of GLA can occur when there is a reduction of the efficiency of the D6D conversion (for instance, as people grow older or when there are specific dietary deficiencies) or in disease states where there is excessive consumption of GLA metabolites.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%223%22])">3</ref></p>

</sec>
<sec>
<st>
A Source of Eicosanoids</st>
<p>

From GLA, the body forms <link xlink:type="simple" xlink:href="../770/3950770.xml">
dihomo-γ-linolenic acid</link> (DGLA). This is one of the body's three sources of <link xlink:type="simple" xlink:href="../312/631312.xml">
eicosanoid</link>s (along with <link xlink:type="simple" xlink:href="../909/267909.xml">
AA</link> and <link xlink:type="simple" xlink:href="../775/1593775.xml">
EPA</link>.) DGLA is the precursor of the <link xlink:type="simple" xlink:href="../336/92336.xml">
prostaglandin</link> PGH1, which in turn forms PGE1 and the <link xlink:type="simple" xlink:href="../732/900732.xml">
thromboxane</link> TXA1. PGE1 has a role in regulation of <link xlink:type="simple" xlink:href="../958/14958.xml">
immune system</link> function and is used as the medicine <link xlink:type="simple" xlink:href="../543/6419543.xml">
alprostadil</link>. TXA1 modulates the pro-inflammatory properties of the thromboxane TXA2.</p>
<p>

Unlike AA and EPA, DGLA cannot yield <link xlink:type="simple" xlink:href="../155/825155.xml">
leukotrienes</link>.  However it can inhibit the formation of pro-inflammatory leukotrienes from AA.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%224%22])">4</ref></p>
<p>

Although GLA is an <it>n</it>−6 fatty acid, a type of acid which is generally pro-inflammatory, it has anti-inflammatory properties. <it>(See discussion at .)</it></p>

</sec>
<sec>
<st>
Health and Medicine</st>
<p>

<image location="left" width="150px" src="Middelste_teunis_bloem_R0011876.JPG" type="thumb">
<caption>

The seed oil of <it>Oenothera biennis</it> (evening primrose) is a source of GLA
</caption>
</image>

GLA is sometimes prescribed in the belief that it has anti-<link xlink:type="simple" xlink:href="../425/70425.xml">
inflammatory</link> properties lacking some of the common <link xlink:type="simple" xlink:href="../833/1274833.xml">
side effects</link> of other <link xlink:type="simple" xlink:href="../071/22071.xml">
anti-inflammatory drug</link>s.  <link xlink:type="simple" xlink:href="../973/439973.xml">
Herbal medicine</link> advocates recommend GLA for <link xlink:type="simple" xlink:href="../046/19468046.xml">
autoimmune disorder</link>s, <link xlink:type="simple" xlink:href="../776/1776.xml">
arthritis</link>, <link xlink:type="simple" xlink:href="../713/57713.xml">
eczema</link> and <link xlink:type="simple" xlink:href="../947/217947.xml">
PMS</link> with noticeable results not expected for months.   Research is ongoing, investigating GLA as a potential <link xlink:type="simple" xlink:href="../219/105219.xml">
anticancer</link> agent.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%225%22])">5</ref>   GLA is unique among the omega-6 <link xlink:type="simple" xlink:href="../981/3321981.xml">
polyunsaturated fatty acid</link>s (linoleic acid, GLA and <link xlink:type="simple" xlink:href="../909/267909.xml">
arachidonic acid</link>) in its potential to suppress tumor growth and metastasis.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%226%22])">6</ref></p>
<p>

GLA can also form a <link xlink:type="simple" xlink:href="../622/18622.xml">
lithium salt</link>, increasing its solubility in water.  The resulting compound is Li-GLA, also called lithium gammalinolenate.  Li-GLA is currently in phase II <link xlink:type="simple" xlink:href="../717/241717.xml">
clinical trials</link> to determine whether it is useful in the treatment of <link xlink:type="simple" xlink:href="../170/14170.xml">
HIV</link> infections, since it has the ability to destroy HIV-infected <link xlink:type="simple" xlink:href="../417/170417.xml">
T cell</link>s <link xlink:type="simple" xlink:href="../188/15188.xml">
in vitro</link>.  It has a number of side-effects, including a reduction in <link xlink:type="simple" xlink:href="../483/13483.xml">
hemoglobin</link>, <link xlink:type="simple" xlink:href="../968/582968.xml">
hematuria</link>, <link xlink:type="simple" xlink:href="../720/69720.xml">
gastrointestinal</link> disturbance, fatigue and headache.<weblink xlink:type="simple" xlink:href="http://www.hivnet.ubc.ca/e/clinicaltrials/R083.html">
 CTN#083,LiGLA</weblink>
</p>
<ss1>
<st>
Atopic Eczema</st>
<p>

Conflicting data are found for GLA in the treatment of <link xlink:type="simple" xlink:href="../713/57713.xml">
eczema</link>. The UK's <link xlink:type="simple" xlink:href="../200/1442200.xml">
Medicines and Healthcare products Regulatory Agency</link> has withdrawn GLA's product licence for atopic eczema.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%227%22])">7</ref> Still, the US <link xlink:type="simple" xlink:href="../174/46174.xml">
National Institute of Health</link>'s MedlinePlus states that there is 'B' grade evidence ('good scientific evidence') for the efficacy of <link xlink:type="simple" xlink:href="../991/589991.xml">
evening primrose oil</link> in the treatment of <link xlink:type="simple" xlink:href="../713/57713.xml">
eczema</link>
and skin <link xlink:type="simple" xlink:href="../481/326481.xml">
irritation</link>.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%228%22])">8</ref>   But it cautions that large well-designed studies are still needed.
A controlled study of borage oil for eczema found no benefit to GLA; it underperformed placebo.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%229%22])">9</ref></p>

</ss1>
</sec>
<sec>
<st>
History</st>

<p>

The medical use of GLA  has been controversial.  <physical_entity wordnetid="100001930" confidence="0.8">
<person wordnetid="100007846" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<academician wordnetid="109759069" confidence="0.8">
<scientist wordnetid="110560637" confidence="0.8">
<adult wordnetid="109605289" confidence="0.8">
<professional wordnetid="110480253" confidence="0.8">
<research_worker wordnetid="110523076" confidence="0.8">
<educator wordnetid="110045713" confidence="0.8">
<link xlink:type="simple" xlink:href="../590/6995590.xml">
David Horrobin</link></educator>
</research_worker>
</professional>
</adult>
</scientist>
</academician>
</causal_agent>
</person>
</physical_entity>
 published much research on the use of GLA (as evening primrose oil) as a dietary supplement for treating <link xlink:type="simple" xlink:href="../073/2225073.xml">
atopic eczema</link>.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2210%22])">10</ref> 
He also founded Scotia Pharmaceuticals, which sold this oil as a pharmaceutical, which led to controversy even after his death.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2211%22])">11</ref></p>

</sec>
<sec>
<st>
References</st>

<p>

<reflist>
<entry id="1">
 <cite style="font-style:normal" class="book">Yung-Sheng Huang, Vincent A. Ziboh&#32;(2001). <weblink xlink:type="simple" xlink:href="http://books.google.com/books?hl=en&amp;lr=&amp;c2coff=1&amp;id=vU5KdI_FXZwC&amp;oi=fnd&amp;pg=PR7&amp;dq=++%22gamma+linolenic+acid%22&amp;ots=9XpUTzP3N7&amp;sig=gSqqGX5E_z-3qqzbs8E47pGoDJE#PPR6,M1">
Gamma-Linolenic Acid: Recent Advances in Biotechnology and Clinical Applications</weblink>.&#32;AOCS Press,&#32;259. ISBN 1893997170. Retrieved on <link>
2007-12-07</link>.</cite>&nbsp;</entry>
<entry id="2">
Gunstone, Frank.&#32;"<weblink xlink:type="simple" xlink:href="http://www.lapinskas.com/publications/3918.html">
Personal Communication at Peter Lapinskas' pages</weblink>".&#32;Retrieved on <link>
2006-02-03</link>.
</entry>
<entry id="3">
 <cite style="font-style:normal">Horrobin DF&#32;(1993).&#32;"<weblink xlink:type="simple" xlink:href="http://www.ajcn.org/cgi/reprint/57/5/732S.pdf">
Fatty acid metabolism in health and disease: the role of delta-6-desaturase</weblink>"&#32;(pdf). <it>Am. J. Clin. Nutr.</it>&#32;<b>57</b>&#32;(5 Suppl): 732S–736S; discussion 736S–737S. PMID 8386433.</cite>&nbsp;</entry>
<entry id="4">
 <cite style="font-style:normal">Belch JJ, Hill A&#32;(2000).&#32;"<weblink xlink:type="simple" xlink:href="http://www.ajcn.org/cgi/content/full/71/1/352S">
Evening primrose oil and borage oil in rheumatologic conditions</weblink>". <it>Am. J. Clin. Nutr.</it>&#32;<b>71</b>&#32;(1 Suppl): 352S–6S. PMID 10617996. Retrieved on <link>
2007-12-07</link>.&#32;“DGLA itself cannot be converted to LTs but can form a 15-hydroxyl derivative that blocks the transformation of arachidonic acid to LTs. Increasing DGLA intake may allow DGLA to act as a competitive inhibitor of 2-series PGs and 4-series LTs and thus suppress inflammation.”</cite>&nbsp;</entry>
<entry id="5">
"<weblink xlink:type="simple" xlink:href="http://news.bbc.co.uk/2/hi/health/4395826.stm">
Plant oil 'acts like cancer drug'</weblink>"&#32;(<link>
2005-11-02</link>). (describing work by Dr Javier Menendez and colleagues at Northwestern University and published in <it>Journal of the National Cancer Institute</it>).</entry>
<entry id="6">
 <cite style="font-style:normal">Fan, Yang-Yi and Robert S. Chapkin&#32;(<link xlink:type="simple" xlink:href="../544/28544.xml">
9 September</link> <link xlink:type="simple" xlink:href="../647/34647.xml">
1998</link>).&#32;"<weblink xlink:type="simple" xlink:href="http://jn.nutrition.org/cgi/content/full/128/9/1411">
Importance of Dietary γ-Linolenic Acid in Human Health and Nutrition</weblink>". <it>Journal of Nutrition</it>&#32;<b>128</b>&#32;(9): 1411–1414. PMID 9732298. Retrieved on <link>
2007-01-05</link>.</cite>&nbsp;</entry>
<entry id="7">
 <cite style="font-style:normal">Smith, Richard&#32;(<link xlink:type="simple" xlink:href="../852/8852.xml">
13 December</link>, <link xlink:type="simple" xlink:href="../163/36163.xml">
2003</link>).&#32;"<weblink xlink:type="simple" xlink:href="http://www.bmj.com/cgi/content/full/327/7428/0-h">
The drugs don't work</weblink>". <it>British Medical Journal</it>&#32;<b>327</b>: 0-h. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1136%2Fbmj.327.7428.0-h">
10.1136/bmj.327.7428.0-h</weblink>. Retrieved on <link>
2007-01-05</link>.</cite>&nbsp;</entry>
<entry id="8">
NIH Medline Plus.&#32;"<weblink xlink:type="simple" xlink:href="http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-primrose.html">
MedlinePlus Herbs and Supplements:  Evening primrose oil</weblink>".&#32;Retrieved on <link xlink:type="simple" xlink:href="../011/16011.xml">
January 19</link>, <link xlink:type="simple" xlink:href="../165/36165.xml">
2007</link>.</entry>
<entry id="9">
 <cite style="font-style:normal">Takwale A, Tan E, Agarwal S, et al&#32;(2003).&#32;"<weblink xlink:type="simple" xlink:href="http://bmj.bmjjournals.com/cgi/content/full/327/7428/1385">
Efficacy and tolerability of borage oil in adults and children with atopic eczema: randomised, double blind, placebo controlled, parallel group trial</weblink>". <it>BMJ</it>&#32;<b>327</b>&#32;(7428): 1385. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1136%2Fbmj.327.7428.1385">
10.1136/bmj.327.7428.1385</weblink>. PMID 14670885.</cite>&nbsp;</entry>
<entry id="10">
 <cite style="font-style:normal">Horrobin, David&#32;(January 2000).&#32;"<weblink xlink:type="simple" xlink:href="http://www.ajcn.org/cgi/content/full/71/1/367S">
Essential fatty acid metabolism and its modification in atopic eczema</weblink>". <it>American Journal of Clinical Nutrition</it>&#32;<b>71</b>&#32;(1): 367S–372s. PMID 10617999. Retrieved on <link>
2007-01-05</link>.</cite>&nbsp;</entry>
<entry id="11">
 <cite style="font-style:normal">Williams, Hywel C&#32;(13 Dec 2003).&#32;"<weblink xlink:type="simple" xlink:href="http://bmj.bmjjournals.com/cgi/content/full/327/7428/1358">
Editorial: Evening primrose oil for atopic dermatitis&mdash;Time to say goodnight</weblink>". <it>BMJ</it>&#32;<b>327</b>: 1358–1359. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1136%2Fbmj.327.7428.1358">
10.1136/bmj.327.7428.1358</weblink>. PMID 14670851. Retrieved on <link>
2007-01-19</link>.</cite>&nbsp; British Medical Journal summary editorial on evening primrose oil in the treatment of eczema
</entry>
</reflist>
</p>

</sec>
<sec>
<st>
See also</st>
<p>

<list>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../316/153316.xml">
Linolenic acid</link></entry>
</list>
</p>
<p>

<table style=";" class="navbox" cellspacing="0">
<row>
<col style="padding:2px;">
<table style="width:100%;background:transparent;color:inherit;;" class="nowraplinks collapsible autocollapse " cellspacing="0">
<row>
<header colspan="2" style=";" class="navbox-title">
<link xlink:type="simple" xlink:href="../940/17940.xml">
Lipid</link>s: <link xlink:type="simple" xlink:href="../975/10975.xml">
fatty acid</link>s</header>
</row>
<row style="height:2px;">

</row>
<row>
<col style=";;" class="navbox-group">
<link xlink:type="simple" xlink:href="../746/264746.xml">
Saturated</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../345/232345.xml">
Butyric</link> • <link xlink:type="simple" xlink:href="../897/2933897.xml">
Hexanoic</link> • <link xlink:type="simple" xlink:href="../774/3127774.xml">
Caprylic</link> • <link xlink:type="simple" xlink:href="../173/2349173.xml">
Decanoic</link> • <link xlink:type="simple" xlink:href="../497/1598497.xml">
Lauric</link> • <link xlink:type="simple" xlink:href="../038/1718038.xml">
Myristic</link> • <link xlink:type="simple" xlink:href="../488/542488.xml">
Palmitic</link> • <link xlink:type="simple" xlink:href="../511/338511.xml">
Stearic</link> • <link xlink:type="simple" xlink:href="../531/542531.xml">
Arachidic</link> • <link xlink:type="simple" xlink:href="../741/3306741.xml">
Behenic</link> • <link xlink:type="simple" xlink:href="../766/3306766.xml">
Lignoceric</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";;" class="navbox-group">
<link xlink:type="simple" xlink:href="../594/22594.xml">
<it>n</it>−3 Unsaturated</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../316/153316.xml">
α-Linolenic</link> • <link xlink:type="simple" xlink:href="../140/3956140.xml">
Stearidonic</link> • <link xlink:type="simple" xlink:href="../775/1593775.xml">
Eicosapentaenoic</link> • <link xlink:type="simple" xlink:href="../318/1673318.xml">
Docosahexaenoic</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";;" class="navbox-group">
<link xlink:type="simple" xlink:href="../218/681218.xml">
<it>n</it>−6 Unsaturated</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../497/880497.xml">
Linoleic</link> • <link xlink:type="simple" xlink:href="../075/806075.xml">
γ-Linolenic</link> • <link xlink:type="simple" xlink:href="../770/3950770.xml">
Dihomo-γ-linolenic</link> • <link xlink:type="simple" xlink:href="../909/267909.xml">
Arachidonic</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";;" class="navbox-group">
<link xlink:type="simple" xlink:href="../439/3110439.xml">
<it>n</it>−9 Unsaturated</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../100/661100.xml">
Oleic</link> • <link xlink:type="simple" xlink:href="../078/302078.xml">
Erucic</link> • <link xlink:type="simple" xlink:href="../057/15602057.xml">
Nervonic</link></col>
</row>
</table>
</col>
</row>
</table>
</p>

<p>

<table style=";" class="navbox" cellspacing="0">
<row>
<col style="padding:2px;">
<table style="width:100%;background:transparent;color:inherit;;" class="nowraplinks collapsible autocollapse " cellspacing="0">
<row>
<header colspan="2" style=";" class="navbox-title">
Other <link xlink:type="simple" xlink:href="../553/74553.xml">
dermatological</link> preparations (<written_communication wordnetid="106349220" confidence="0.8">
<code wordnetid="106667317" confidence="0.8">
<link xlink:type="simple" xlink:href="../594/832594.xml">
D11</link></code>
</written_communication>
)</header>
</row>
<row style="height:2px;">

</row>
<row>
<col style=";background-color: Linen;" class="navbox-group">
Medicated <link xlink:type="simple" xlink:href="../002/18842002.xml">
shampoo</link>s</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../929/3441929.xml">
Cetrimide</link> - <link xlink:type="simple" xlink:href="../672/5672.xml">
Cadmium</link> compounds - <link xlink:type="simple" xlink:href="../117/27117.xml">
Selenium</link> compounds - <link xlink:type="simple" xlink:href="../669/1817669.xml">
Povidone-iodine</link> - <link xlink:type="simple" xlink:href="../127/27127.xml">
Sulfur</link> compounds - <link>
Xenysalate</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background-color: Linen;" class="navbox-group">
Other dermatologicals</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<it><link xlink:type="simple" xlink:href="../863/465863.xml">
seborrhoeic dermatitis</link>/<link xlink:type="simple" xlink:href="../023/393023.xml">
dandruff</link></it> (<substance wordnetid="100019613" confidence="0.8">
<compound wordnetid="114818238" confidence="0.8">
<compound wordnetid="105870180" confidence="0.8">
<chemical wordnetid="114806838" confidence="0.8">
<part wordnetid="113809207" confidence="0.8">
<material wordnetid="114580897" confidence="0.8">
<salt wordnetid="115010703" confidence="0.8">
<link xlink:type="simple" xlink:href="../865/12938865.xml">
Lithium succinate</link></salt>
</material>
</part>
</chemical>
</compound>
</compound>
</substance>
, <preparation wordnetid="101143040" confidence="0.8">
<event wordnetid="100029378" confidence="0.8">
<act wordnetid="100030358" confidence="0.8">
<psychological_feature wordnetid="100023100" confidence="0.8">
<activity wordnetid="100407535" confidence="0.8">
<link xlink:type="simple" xlink:href="../584/697584.xml">
Pyrithione zinc</link></activity>
</psychological_feature>
</act>
</event>
</preparation>
) <p>

<it><link xlink:type="simple" xlink:href="../369/4397369.xml">
skin whitening/depigmenting</link></it> (<substance wordnetid="100020090" confidence="0.8">
<substance wordnetid="100019613" confidence="0.8">
<carcinogen wordnetid="114793812" confidence="0.8">
<chemical wordnetid="114806838" confidence="0.8">
<part wordnetid="113809207" confidence="0.8">
<material wordnetid="114580897" confidence="0.8">
<link xlink:type="simple" xlink:href="../515/1703515.xml">
Hydroquinone</link></material>
</part>
</chemical>
</carcinogen>
</substance>
</substance>
, <link xlink:type="simple" xlink:href="../750/12938750.xml">
Mequinol</link>, <link xlink:type="simple" xlink:href="../049/12437049.xml">
Monobenzone</link>)</p>
<p>

<it><link xlink:type="simple" xlink:href="../241/726241.xml">
anti-inflammatory</link>/<link xlink:type="simple" xlink:href="../713/57713.xml#xpointer(//*[./st=%22Immunomodulators%22])">
Immunomodulators</link></it> (<link xlink:type="simple" xlink:href="../718/12938718.xml">
Oxaceprol</link>, <link xlink:type="simple" xlink:href="../075/806075.xml">
Gamolenic acid</link>), <physical_entity wordnetid="100001930" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<agent wordnetid="109190918" confidence="0.8">
<link xlink:type="simple" xlink:href="../751/915751.xml">
Pimecrolimus</link></agent>
</causal_agent>
</physical_entity>
, <physical_entity wordnetid="100001930" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<agent wordnetid="109190918" confidence="0.8">
<link xlink:type="simple" xlink:href="../010/159010.xml">
Tacrolimus</link></agent>
</causal_agent>
</physical_entity>
)</p>
<p>

<it><link xlink:type="simple" xlink:href="../966/1903966.xml">
baldness treatments</link></it> (<substance wordnetid="100020090" confidence="0.8">
<inhibitor wordnetid="114724436" confidence="0.8">
<link xlink:type="simple" xlink:href="../311/1245311.xml">
Finasteride</link></inhibitor>
</substance>
, <link xlink:type="simple" xlink:href="../527/429527.xml">
Minoxidil</link>)</p>
<p>

<it>hair growth inhibiting agent</it> (<link xlink:type="simple" xlink:href="../225/1453225.xml">
Eflornithine</link>)</p>
<p>

<it>other</it> (<compound wordnetid="105870180" confidence="0.8">
<link xlink:type="simple" xlink:href="../106/6146106.xml">
Calcium gluconate</link></compound>
, <link xlink:type="simple" xlink:href="../267/246267.xml">
Magnesium sulfate</link>, <physical_entity wordnetid="100001930" confidence="0.8">
<substance wordnetid="100020090" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<agent wordnetid="114778436" confidence="0.8">
<drug wordnetid="103247620" confidence="0.8">
<link xlink:type="simple" xlink:href="../862/12634862.xml">
Tiratricol</link></drug>
</agent>
</causal_agent>
</substance>
</physical_entity>
)</p>
</col>
</row>
</table>
</col>
</row>
</table>
</p>



</sec>
</bdy>
</article>
